---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-014952"
form_type: "8-K"
ticker: "NXTS"
cik: "0001789192"
company_name: "Nexentis Technologies Inc."
filed_at: "2025-09-25T23:59:59+00:00"
generated_at: "2026-05-17T05:40:58.492876+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# N2OFF shareholders approve acquisition of MitoCareX Bio; closing targeted by early Oct 2025

## Summary
- Stockholders voted 11.7M for, 197K against to approve the MitoCareX acquisition; reverse split and warrant share proposals also passed.
- N2OFF will acquire MitoCareX from SciSparc (SPRC) and others for $700K plus shares equal to 40% of fully diluted stock.
- Sellers get 30% of financing proceeds (capped at $1.6M) for 5 years and milestone issuances up to 25% of common stock.
- N2OFF commits an initial $1M cash investment to support MitoCareX operations for two years post-closing.
- A 1-for-35 reverse stock split was already effected on Sept 22; the approved split range (1:2 to 1:150) allows further action within one year.

## SEC filing metadata
- accession: 0001493152-25-014952
- form_type: 8-K
- ticker: NXTS
- cik: 0001789192
- company_name: Nexentis Technologies Inc.
- filed_at: 2025-09-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789192/000149315225014952/0001493152-25-014952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789192/000149315225014952/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-014952
- JSON: https://secwatch.observer/filing/0001493152-25-014952.json
- Plain text: https://secwatch.observer/filing/0001493152-25-014952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.